Comparisons between responders and non-responders to colestipol treatment (responder definition: reporting adequate relief ≥50% of weeks 5–8)
| Responders (n=15) | Non-responders (n=12) | p Value | |
|---|---|---|---|
| Age, years | 42.3 (11.5) | 40.2 (15.8) | 0.71 |
| 75SeHCAT, % | 8.8 (5.0) | 10.4 (4.9) | 0.43 |
| C4, ng/mL | 55.3 (76.7) | 31.5 (24.3) | 0.31 |
| C4c, mg/mol | 10.3 (18.9) | 6.0 (3–4) | 0.45 |
| FGF19, pg/mL | 113.0 (109.1)) | 113.2 (71.9) | 0.99 |
| Total cholesterol, mmol/L | 4.83 (1.43) | 6.5 (1.6) | 0.02 |
| Triglyceride, mmol/L | 1.7 (1.3) | 1.5 (1.0) | 0.68 |
| HDL-cholesterol, mmol/L | 1.6 (0.4) | 1.4 (0.2) | 0.10 |
| BMI, kg/m2 | 25.7 (4.9) | 24.3 (5.0) | 0.49 |
| Stool frequency (stools/day) | 2.6 (1.2) | 3.1 (1.5) | 0.37 |
| Stool consistency (BSF score) | 4.0 (1.3) | 4.7 (1.5) | 0.22 |
| Colonic transit time, days | 0.8 (0.4) | 1.2 (0.8) | 0.22 |
| Rectal pain threshold, mm Hg | 42.0 (14.0) | 39.4 (13.0) | 0.73 |
Significant differences (p<0.05) shown with bold style. Mean (SD).
BMI, body mass index; BSF, Bristol Stool Form; C4, 7α-hydroxy-4-cholesten-3-one; C4c, C4 corrected for cholesterol; FGF19, fibroblast growth factor 19; 75SeHCAT, 75Se-labelled homocholic acid-taurine.